Montrouge, France, May 2, 2017
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences:
Susanna Mesa, Senior Vice President, Strategy, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV, on Wednesday, May 17, 2017, at 9:20 am PT.
Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Sébastien Robitaille, Deputy Chief Financial Officer, will host investor meetings at the Gilbert Dupont 15th Annual Healthcare Conference on Tuesday, May 30, 2017, in Paris, France.
Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, June 1, 2017, at 10:30 am PT.
Pierre-Henri Benhamou, Chairman & Chief Executive Officer, and David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, will host investor meetings at the Société Générale 12th Edition of the Nice Conference on Friday, June 2, 2017, in Nice, France.
A live webcast of the Bank of America Merrill Lynch 2017 Health Care Conference will be available on the Investor Relations section of the Company’s website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV’s website within three hours after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
